Adipose tissue inflammation and altered adipokine and cytokine production in antiretroviral therapy-associated lipodystrophy

Current Opinion in HIV and AIDS

Volumn 2, Issue 4, 2007, Pages 274-281

  Hammond, Emma ^a   Nolan, David ^a,b  

^a MURDOCH UNIVERSITY   (Australia)

^b ROYAL PERTH HOSPITAL   (Australia)

Author keywords

Adipose tissue; Cytokines; Inflammation; Lipodystrophy

Indexed keywords

ABACAVIR; ADIPONECTIN; CYTOKINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADIPOSE TISSUE; CARBOHYDRATE METABOLISM; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG CHOICE; DRUG EFFECT; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSLIPIDEMIA; HIV ASSOCIATED LIPODYSTROPHY; HORMONAL REGULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; INSULIN RESISTANCE; LIPID METABOLISM; LIPOATROPHY; LIPOLYSIS; LIPOPROTEIN BLOOD LEVEL; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SUBCUTANEOUS FAT; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 34250680829     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3281c10df7     Document Type: Review

References (86)

1. John M, Nolan D, Mallal S. Antiretroviral therapy and the lipodystrophy syndrome. Antivir Ther 2001; 6:9-20.
2. Nolan D, John M, Mallal S. Antiretroviral therapy and the lipodystrophy syndrome, part 2: concepts in aetiopathogenesis. Antivir Ther 2001; 6: 145-160.
3. Mulligan K, Parker RA, Komarow L, et al. Mixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized trial. J Acquir Immune Defic Syndr 2006; 41:590-597. A key paper that utilizes body composition data from the ACTG 384 study (zidovudine versus stavudine; nelfinavir versus efavirenz) to show that there was no evidence that central fat accumulation and peripheral fat loss are linked in most patients.
4. Bacchetti P, Gripshover B, Grunfeld C, et al. Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr 2005; 40:121-131.
5. Nolan D, Hammond E, James I, et al. Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level. Antivir Ther 2003; 8:617-626.
6. Nolan D, Hammond E, Martin A, et al. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. AIDS 2003; 17:1329-1338.
7. Hammond E, Nolan D, James I, et al. Reduction of mitochondrial DNA content and respiratory chain activity occurs in adipocytes within 6-12 months of commencing nucleoside reverse transcriptase inhibitor therapy. AIDS 2004; 18:815-817.
8. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999; 354:1112-1115.
9. Young J, Rickenbach M, Weber R, et al. Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study. Antivir Ther 2005; 10:73-81.
10. Amin J, Moore A, Carr A, et al. Combined analysis of two-year follow-up from two open-label randomized trials comparing efficacy of three nucleoside reverse transcriptase inhibitor backbones for previously untreated HIV-1 infection: OzCombo 1 and 2. HIV Clin Trials 2003; 4:252-261.
11. Law M, Puls R, Cheng AK, et al. Evaluation of the HIV lipodystrophy case definition in a placebo-controlled, 144-week study in antiretroviral-naive adults. Antivir Ther 2006; 11:179-186. This study applied the HIV Lipodystrophy Case Definition to data from the Gilead 903 study to show that lipodystrophy (particularly moderate-to-severe grade) was strongly and specifically associated with stavudine therapy in protease inhibitor-naïve patients.
12. Bastard JP, Caron M, Vidal H, et al. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocytes differentiation. Lancet 2002; 359:1026-1031.
13. Jan V, Cervera P, Maachi M, et al. Altered fat differentiation and adipocytokine expression are inter-related and linked to morphological changes and insulin resistance in HIV-1-infected lipodystrophic patients. Antivir Ther 2004; 9:555-564.
14. Lagathu C, Kim M, Maachi M, et al. HIV antiretroviral treatment alters adipokine expression and insulin sensitivity of adipose tissue in vitro and in vivo. Biochimie 2005; 87:65-71.
15. Jones SP, Janneh O, Back DJ, Pirmohamed M. Altered adipokine response in murine 3T3-F442A adipocytes treated with protease inhibitors and nucleoside reverse transcriptase inhibitors. Antivir Ther 2005; 10:207-213.
16. Kannisto K, Sutinen J, Korsheninnikova E, et al. Expression of adipogenic transcription factors, peroxisome proliferator-activated receptor gamma co-activator 1, IL-6 and CD45 in subcutaneous adipose tissue in lipodystrophy associated with highly active antiretroviral therapy. AIDS 2003; 17:1753-1762.
17. Vigouroux C, Maachi M, Nguyen TH, et al. Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy. AIDS 2003; 17:1503-1511.
18. Kim RJ, Wilson CG, Wabitsch M, et al. HIV protease inhibitor-specific alterations in human adipocyte differentiation and metabolism. Obesity (Silver Spring) 2006; 14:994-1002.
19. Jackson MB, Osei SY, Ahima RS. The endocrine role of adipose tissue: focus on adiponectin and resistin. Curr Opin Endocrinol Diabetes 2005; 12:163-170.
20. Flier JS. Obesity wars: molecular progress confronts an expanding epidemic. Cell 2004; 116:337-350.
21. Frayn KN, Arner P, Yki-Jarvinen H. Fatty acid metabolism in adipose tissue, muscle and liver in health and disease. Essays Biochem 2006; 42:89-103. An informative review emphasizing the dynamic nature of fatty acid metabolism, and the role of adipose tissue in this process, in health and disease.
22. Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 2005; 96:939-949.
23. O'Rahilly S. Human obesity and insulin resistance: lessons from experiments of Nature. Biochem Soc Trans 2007; 35:33-36. Examines lipodystrophy syndromes and their implications for understanding the relationships between insulin resistance and adipose tissue.
24. Hegele RA. Monogenic forms of insulin resistance: apertures that expose the common metabolic syndrome. Trends Endocrinol Metab 2003; 14:371-377.
25. Capeau J, Magre J, Lascols O, et al. Diseases of adipose tissue: genetic and acquired lipodystrophies. Biochem Soc Trans 2005; 33:1073-1077.
26. Mary-Krause M, Cotte L, Simon A, et al. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003; 17:2479-2486.
27. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and risk of myocardial infarction. N Engl J Med 2003; 349:1993-2003.
28. Kwong GP, Ghani AC, Rode RA, et al. Comparison of the risks of atherosclerotic events versus death from other causes associated with antiretroviral use. AIDS 2006; 20:1941-1950.
29. Pereira RI, Draznin B. Inhibition of the phosphatidylinositol 3′-kinase signaling pathway leads to decreased insulin-stimulated adiponectin secretion from 3T3-L1 adipocytes. Metabolism 2005; 54:1636-1643.
30. Fu Y, Luo N, Klein RL, Garvey WT. Adiponectin promotes adipocyte differentiation, insulin sensitivity, and lipid accumulation. J Lipid Res 2005; 46:1369-1379.
31. Seo JB, Moon HM, Noh MJ, et al. Adipocyte determination- and differentiation-dependent factor 1/sterol regulatory element-binding protein 1c regulates mouse adiponectin expression. J Biol Chem 2004; 279:22108-22117.
32. Kamigaki M, Sakaue S, Tsujino I, et al. Oxidative stress provokes atherogenic changes in adipokine gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Commun 2006; 339:624-632. Important demonstration of the role of adipocyte oxidative stress in the regulation of adiponectin levels.
33. Soares AF, Guichardant M, Cozzone D, et al. Effects of oxidative stress on adiponectin secretion and lactate production in 3T3-L1 adipocytes. Free Radic Biol Med 2005; 38:882-889.
34. Lagathu C, Yvan-Charvet L, Bastard JP, et al. Long-term treatment with interleukin-1beta induces insulin resistance in murine and human adipocytes. Diabetologia 2006; 49:2162-2173. Clear demonstration of the effects of proinflammatory cytokines on insulin resistance in adipocytes, highlighting the importance of autocrine signaling in adipose tissue.
35. Simons PJ, van den Pangaart PS, Aerts JM, Boon L. Pro-inflammatory delipidizing cytokines reduce adiponectin secretion from human adipocytes without affecting adiponectin oligomerization. J Endocrinol 2007; 192:289-299.
36. Ouchi N, Kihara S, Arita Y, et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001; 103:1057-1063.
37. Yamaguchi N, Argueta JG, Masuhiro Y, et al. Adiponectin inhibits toll-like receptor family-induced signaling. FEBS Lett 2005; 579:6821-6826.
38. Yamauchi T, Nio Y, Maki T, et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 2007; 1 February [Epub ahead of print]. Recent seminal study showing the essential role of adiponectin in regulating whole-body metabolism.
39. Chan DC, Watts GF, Ng TW, et al. Adiponectin and other adipocytokines as predictors of markers of triglyceride-rich lipoprotein metabolism. Clin Chem 2005; 51:578-585.
40. Whitehead JP, Richards AA, Hickman IJ, et al. Adiponectin: a key adipokine in the metabolic syndrome. Diabetes Obes Metab 2006; 8:264-280.
41. Fain JN, Madan AK, Hiler ML, et al. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 2004; 145:2273-2282.
42. Fain JN, Tichansky DS, Madan AK, et al. Most of the interleukin 1 receptor antagonist, cathepsin S, macrophage migration inhibitory factor, nerve growth factor, and interleukin 18 release by explants of human adipose tissue is by the nonfat cells, not by the adipocytes. Metabolism 2006; 55:1113-1121. Demonstration of the differential functions of adipocytes and adipose tissue macrophages in secreting adipocytokines.
43. Weisberg SP, McCann D, Desai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112:1796-1808.
44. Lumeng CN, Deyoung SM, Bodzin JL, Saltiel AR. Increased inflammatory properties of adipose tissue macrophages recruited during diet-induced obesity. Diabetes 2007; 56:16-23.
45. Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest 2007; 117:175-184. Identifies diverse functions for adipose tissue macrophages, which may be antiinflammatory or proinflammatory depending on the context.
46. Podzamczer D, Ferrer E, Sanchez P, et al. Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study. J Acquir Immune Defic Syndr 2007; 44:139-147. Very recent report of an important clinical trial, comparing abacavir versus stavudine treatment (in protease inhibitor-naïve patients) with lipodystrophy outcomes as prominent study endpoints.
47. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191-201.
48. Buffet M, Schwarzinger M, Amellal B, et al. Mitochondrial DNA depletion in adipose tissue of HIV-infected patients with peripheral lipoatrophy. J Clin Virol 2005; 33:60-64.
49. Walker UA, Bickel M, Lutke Volksbeck SI, et al. Evidence of nucleoside analogue reverse transcriptase inhibitor-associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patients. J Acquir Immune Defic Syndr 2002; 29:117-121.
50. Cherry CL, Nolan D, James IR, et al. Tissue-specific associations between mitochondrial DNA levels and current treatment status in HIV-infected individuals. J Acquir Immune Defic Syndr 2006; 42:435-440.
51. Cherry CL, Lal L, Thompson KA, et al. Increased adipocyte apoptosis in lipoatrophy improves within 48 weeks of switching patient therapy from stavudine to abacavir or zidovudine. J Acquir Immune Defic Syndr 2005; 38:263-267.
52. Joly V, Flandre P, Meiffredy V, et al. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. AIDS 2002; 16:2447-2454.
53. Dube MP, Parker RA, Tebas P, et al. Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS 2005; 19:1807-1818.
54. Mallal SA, John M, Moore CB, et al. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000; 14:1309-1316.
55. Addy CL, Gavrila A, Tsiodras S, et al. Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy. J Clin Endocrinol Metab 2003; 88:627-636.
56. Lihn AS, Richelsen B, Pedersen SB, et al. Increased expression of TNF-alpha, IL-6, and IL-8 in HALS: implications for reduced adiponectin expression and plasma levels. Am J Physiol Endocrinol Metab 2003; 285:E1072-E1080.
57. Mynarcik DC, Combs T, McNurlan MA, et al. Adiponectin and leptin levels in HIV-infected subjects with insulin resistance and body fat redistribution. J Acquir Immune Defic Syndr Hum Retrovirol 2002; 31:514-520.
58. Tong Q, Sankale JL, Hadigan CM, et al. Regulation of adiponectin in human immunodeficiency virus-infected patients: relationship to body composition and metabolic indices. J Clin Endocrinol Metab 2003; 88:1559-1564.
59. Jones SP, Qazi N, Morelese J, et al. Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine- and zidovudine-containing regimens. J Acquir Immune Defic Syndr 2005; 40:565-572.
60. Sutinen J, Korsheninnikova E, Funahashi T, et al. Circulating concentration of adiponectin and its expression in subcutaneous adipose tissue in patients with highly active antiretroviral therapy-associated lipodystrophy. J Clin Endocrinol Metab 2003; 88:1907-1910.
61. Kosmiski L, Kuritzkes D, Lichtenstein K, Eckel R. Adipocyte-derived hormone levels in HIV lipodystrophy. Antivir Ther 2003; 8:9-15.
62. Lindegaard B, Keller P, Bruunsgaard H, et al. Low plasma level of adiponectin is associated with stavudine treatment and lipodystrophy in HIV-infected patients. Clin Exp Immunol 2004; 135:273-279.
63. Haugaard SB, AndersenO, Pedersen SB, et al. Tumor necrosis factor alpha is associated with insulin-mediated suppression of free fatty acids and net lipid oxidation in HIV-infected patients with lipodystrophy. Metabolism 2006; 55:175-182. Clinical study relating cytokine and metabolic profiles in the context of HIV treatment-associated lipodystrophy, from a productive and thoughtful research group.
64. Lindegaard B, Hansen AB, Pilegaard H, et al. Adipose tissue expression of IL-18 and HIV-associated lipodystrophy. AIDS 2004; 18:1956-1958.
65. Brown TT, Li X, Cole SR, et al. Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS 2005; 19:1375-1383.
66. Jones R, Sawleshwarkar S, Michailidis C, et al. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone. HIV Med 2005; 6:396-402.
67. Duong M, Petit JM, Martha B, et al. Concentration of circulating oxidized LDL in HIV-infected patients treated with antiretroviral agents: relation to HIV-related lipodystrophy. HIV Clin Trials 2006; 7:41-47.
68. Fisac C, Virgili N, Ferrer E, et al. Changes in insulin resistance markers and cytokines in antiretroviral-naïve HIV-patients 24 months after initiating stavudine- or abacavir-containing therapies. In: 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment; 24-27 July 2005; Rio de Janeiro. Abstract No. TuPeLB2.2B02.
69. Petit JM, Duong M, Masson D, et al. Serum adiponectin and metabolic parameters in HIV-1-infected patients after substitution of nevirapine for protease inhibitors. Eur J Clin Invest 2004; 34:569-575.
70. Petit C, Pietri-Rouxel F, Lesne A, et al. Oxygen consumption by cultured human cells is impaired by a nucleoside analogue cocktail that inhibits mitochondrial DNA synthesis. Mitochondrion 2005; 5:154-161.
71. Deveaud C, Beauvoit B, Reynaud A, Bonnet J. Site-specific reduction of oxidative and lipid metabolism in adipose tissue of 3′-azido-3′- deoxythymidine-treated rats. Antimicrob Agents Chemother 2007; 51:583-590.
72. Daval M, Foufelle F, Ferre P. Functions of AMP-activated protein kinase in adipose tissue. J Physiol 2006; 574:55-62.
73. Boyd MA, Carr A, Ruxrungtham K, et al. Changes in body composition and mitochondrial nucleic acid content in patients switched from failed nucleoside analogue therapy to ritonavir-boosted indinavir and efavirenz. J Infect Dis 2006; 194:642-650. Interesting clinical study involving treatment switching in which NRTI drugs associated with lipodystrophy were replaced by a NRTI-sparing regimen consisting of ritonavir-indinavir plus efavirenz. A clear demonstration of the differential effects of NRTI and protease inhibitor drugs in the context of HIV lipodystrophy.
74. Carr A, Workman C, Smith DE, et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA 2002; 288:207-215.
75. Martin A, Smith DE, Carr A, et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS 2004; 18:1029-1036.
76. Kim M, Leclercq P, Cervera P, et al. A six-months ART interruption in HIV-infected patients improves adipose tissue morphology and gene expression. Antivir Ther 2006; 11:L6.
77. Rudich A, Ben-Romano R, Etzion S, Bashan N. Cellular mechanisms of insulin resistance, lipodystrophy and atherosclerosis induced by HIV protease inhibitors. Acta Physiol Scand 2005; 183:75-88.
78. Hruz PW. Molecular mechanisms for altered glucose homeostasis in HIV infection. Am J Infect Dis 2006; 2:187-192.
79. Nolan D. Metabolic complications associated with HIV protease inhibitor therapy. Drugs 2003; 63:2555-2574.
80. Caron M, Auclair M, Sterlingot H, et al. Some HIV protease inhibitors alter lamin A/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation. AIDS 2003; 17:2737-2444.
81. Lee GA, Rao MN, Grunfeld C. The effects of HIV protease inhibitors on carbohydrate and lipid metabolism. Curr HIV/AIDS Rep 2005; 2:39-50.
82. Hansen BR, Haugaard SB, Iversen J, et al. Impact of switching antiretroviral therapy on lipodystrophy and other metabolic complications: a review. Scand J Infect Dis 2004; 36:244-253.
83. Barragan P, Fisac C, Podzamczer D. Switching strategies to improve lipid profile and morphologic changes. AIDS Rev 2006; 8:191-203.
84. Chew GT, Gan SK, Watts GF. Revisiting the metabolic syndrome. Med J Aust 2006; 185:445-449.
85. Swainston Harrison T, Scott LJ. Atazanavir: a review of its use in the management of HIV infection. Drugs 2005; 65:2309-2336.
86. Schambelan M, Benson CA, Carr A, et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society - USA panel. J Acquir Immune Defic Syndr 2002; 31:257-275.